Invion Ltd has released a press release.
Response to ASX Price Query
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Invion
- Orphan Drug Designation Granted by U.S. FDA For Anal Cancer
- Appendix 4C and Quarterly Activities Report - June 2025
- Security Class Reinstatement to Quotation
- Security Class Suspension from Quotation
- Underwritten Loyalty Option Entitlement Offer Prospectus
Later from Invion
- Appendix 4E and Annual Report
- Response to ASX Aware Letter
- Repayment of Lind Facility with Successful Capital Raise
- Funded Collaboration Agreement with Protect Animal Health
- Appendix 4C and Quarterly Activities Report - September 2025
Follow Invion into a list and get an email when it puts out news.
Follow Invion